Google's DeepMind eyes clinical trials for AI-designed drugs
AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.
This new approach, based on natural selection, dramatically improves the reliability of large language models for practical ...
A demo car ad created with Veo 2 from Google DeepMind is so realistic that it's hard to spot the amazing locations, ...
The company fulfilled requests from Israel’s military for more access to AI tools as it sought to compete with Amazon, ...
The director of the corporation’s scientific laboratory points to genomics, nuclear fusion and the development of new materials as future areas of exploration for his team ...
The order, signed in October 2023, required companies building powerful AI systems to share their safety test results with the federal government and come up with ways to limit their models’ biases ...
Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups ...
With "Mind Evolution" LLMs can use search and genetic algorithms to generate and combine different solutions and find the optimal one.
Project Astra uses your phone camera or camera-equipped glasses to see the world around it and analyze what it sees.
Business Insider's diary takes you behind the scenes on day three of the World Economic Forum in Davos.
AI creatives with access to Google’s Veo 2 text-to-video tool say it’s another “leap forward” for video generation Veo 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback